The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00389779




Registration number
NCT00389779
Ethics application status
Date submitted
17/10/2006
Date registered
19/10/2006
Date last updated
18/03/2014

Titles & IDs
Public title
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
Scientific title
A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)
Secondary ID [1] 0 0
Protocol DAR-312
Universal Trial Number (UTN)
Trial acronym
Darusentan
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Darusentan
Treatment: Drugs - Guanfacine
Treatment: Drugs - Darusentan Placebo

Experimental: Darusentan - Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks

Active Comparator: Guanfacine - Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks

Placebo Comparator: Darusentan Placebo - Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks


Treatment: Drugs: Darusentan
Darusentan capsules administered orally once daily

Treatment: Drugs: Guanfacine
Guanfacine capsules administered orally once daily

Treatment: Drugs: Darusentan Placebo
Placebo to match darusentan administered orally once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry
Timepoint [1] 0 0
Baseline to Week 14
Secondary outcome [1] 0 0
Percentage of subjects reaching systolic blood pressure goal after 14 weeks of treatment
Timepoint [1] 0 0
Week 14
Secondary outcome [2] 0 0
Change from baseline in mean 24-hour systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM)
Timepoint [2] 0 0
Baseline to Week 14
Secondary outcome [3] 0 0
Change from baseline in estimated glomerular filtration rate (eGFR)
Timepoint [3] 0 0
Baseline to Week 14

Eligibility
Key inclusion criteria
SELECTED INCLUSION CRITERIA:

1. Subjects who are competent to provide written consent;

2. Aged 35 to 80 years;

3. Subjects with diabetes and/or chronic kidney disease must have an average sitting
systolic blood pressure greater than or equal to 130 mmHg;

4. All other subjects must have an average sitting systolic blood pressure greater than
or equal to 140 mmHg;

5. Receiving and adhering to full doses of appropriate guideline-recommended
antihypertensive drugs from three different classes of antihypertensive agents,
including a diuretic;

6. Female subjects of non-childbearing potential (i.e., post-menopausal for at least 2
years or surgically sterile).

SELECTED EXCLUSION CRITERIA:

1. Average sitting systolic and diastolic blood pressure greater than or equal to 180
mmHg and 110 mmHg, respectively;

2. Subjects treated with a central alpha-2 agonist and/or imidazoline receptor agonist;

3. Left ventricular dysfunction;

4. Serum ALT or AST greater than 2 times the Upper Limit of Normal;

5. Subjects who have experienced myocardial infarction, unstable angina pectoris, or a
cerebrovascular accident within 6 months; or sick sinus syndrome or second or third
degree atrioventricular block, atrial fibrillation or recurrent atrial tachycardia,
recurrent ventricular tachycardia, or symptomatic bradycardia;

6. Implanted pacemakers or cardioverter defibrillator;

7. Symptomatic congestive heart failure requiring treatment;

8. Hemodynamically significant valvular heart disease;

9. Hemodialysis or peritoneal dialysis, or history of renal transplant;

10. Type I diabetes mellitus;

11. Diagnosis or recurrence of malignancy within the past 3 years;

12. Sleep apnea, unless a recent sleep study demonstrated arterial oxygenation saturation
greater than or equal to 90%, treated or untreated;

13. Subjects who perform alternating shift or night work;

14. Subjects who have participated in a clinical study involving another investigational
drug or device within 4 weeks prior to Screening
Minimum age
35 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment hospital [3] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Montana
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Rhode Island
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Vermont
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Ciudad de Buenos Aires
Country [32] 0 0
Argentina
State/province [32] 0 0
Ciudad de
Country [33] 0 0
Argentina
State/province [33] 0 0
Cordoba
Country [34] 0 0
Argentina
State/province [34] 0 0
Corrientes
Country [35] 0 0
Argentina
State/province [35] 0 0
La Plata
Country [36] 0 0
Argentina
State/province [36] 0 0
Quilmes
Country [37] 0 0
Argentina
State/province [37] 0 0
Rosario
Country [38] 0 0
Argentina
State/province [38] 0 0
Santa Fe
Country [39] 0 0
Belgium
State/province [39] 0 0
Brussel
Country [40] 0 0
Belgium
State/province [40] 0 0
De Pinte
Country [41] 0 0
Belgium
State/province [41] 0 0
Genk
Country [42] 0 0
Belgium
State/province [42] 0 0
Hoeilaart
Country [43] 0 0
Belgium
State/province [43] 0 0
Natoye
Country [44] 0 0
Belgium
State/province [44] 0 0
Pulle
Country [45] 0 0
Belgium
State/province [45] 0 0
Riemst
Country [46] 0 0
Belgium
State/province [46] 0 0
Tielt
Country [47] 0 0
Belgium
State/province [47] 0 0
Wetteren
Country [48] 0 0
Brazil
State/province [48] 0 0
Rio de Janeiro
Country [49] 0 0
Denmark
State/province [49] 0 0
Aalborg
Country [50] 0 0
Denmark
State/province [50] 0 0
Naestved
Country [51] 0 0
France
State/province [51] 0 0
Blois
Country [52] 0 0
France
State/province [52] 0 0
Dommartin les Toul
Country [53] 0 0
France
State/province [53] 0 0
La Jubaudiere
Country [54] 0 0
France
State/province [54] 0 0
Le Mesnil en vallee
Country [55] 0 0
France
State/province [55] 0 0
Le Temple-de-Bretagne
Country [56] 0 0
France
State/province [56] 0 0
Martigues
Country [57] 0 0
France
State/province [57] 0 0
Murs-Erigne
Country [58] 0 0
France
State/province [58] 0 0
Nantes
Country [59] 0 0
France
State/province [59] 0 0
Vihiers
Country [60] 0 0
Germany
State/province [60] 0 0
Bad Worishofen
Country [61] 0 0
Germany
State/province [61] 0 0
Berlin
Country [62] 0 0
Germany
State/province [62] 0 0
Frankfurt
Country [63] 0 0
Germany
State/province [63] 0 0
Hamburg
Country [64] 0 0
Germany
State/province [64] 0 0
Heidelberg
Country [65] 0 0
Germany
State/province [65] 0 0
Koeln
Country [66] 0 0
Germany
State/province [66] 0 0
Ruedersdorf
Country [67] 0 0
New Zealand
State/province [67] 0 0
Auckland
Country [68] 0 0
New Zealand
State/province [68] 0 0
Christchurch
Country [69] 0 0
New Zealand
State/province [69] 0 0
Greenlane
Country [70] 0 0
New Zealand
State/province [70] 0 0
Hamilton
Country [71] 0 0
New Zealand
State/province [71] 0 0
Tauranga
Country [72] 0 0
Spain
State/province [72] 0 0
Barcelona
Country [73] 0 0
Spain
State/province [73] 0 0
Elche

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo- and active-controlled study of a new
experimental drug called darusentan. Darusentan is not currently approved by the United
States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this
drug. The purpose of this study is to determine if darusentan is effective in reducing
systolic and diastolic hypertension despite treatment with full doses of three or more
antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan
(optimized dose), an active comparator, or placebo, administered orally. The treatment period
for this trial is 14 weeks.
Trial website
https://clinicaltrials.gov/show/NCT00389779
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications